MarketPulse
A

$AMGN

14 articles found
6 positive
0 negative
8 neutral
The Motley FoolThe Motley Fool··James Halley

Two Biotech Darlings Poised for Acquisition: Abivax and Nektar Signal M&A Targets

Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.
AMGNABBVLLYAZNABVX+1acquisitionbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Cytomx Therapeutics, Inc.

CytomX Raises $250M via Stock Offering to Fund Varseta-M Development

CytomX Therapeutics prices $250M stock offering at $5.30/share to fund Varseta-M development and pipeline advancement, closing March 2026.
AMGNBMYCELGrREGNMRNA+1colorectal cancerpublic offering
BenzingaBenzinga··Namrata Sen

Amgen, GSK Join TrumpRx Platform With Deep Discounts as Drug Pricing Pressure Mounts

Amgen and GSK join TrumpRx.gov offering up to 80% and 10-55% discounts respectively, expanding the platform to 54 drugs amid Trump administration pricing pressure.
AMGNPFELLYNVOAZN+1pharmaceutical companiesdrug affordability
The Motley FoolThe Motley Fool··Selena Maranjian

Dividend ETF Strategy: How $100 Monthly Could Grow to $67K in Two Decades

Schwab's Dividend ETF ($SCHD) could turn $100 monthly into $67K in 20 years through 13% historical returns and 3.3% dividend yield.
AMGNBMYCELGrVZSCHD+1passive incomelong-term investing
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

GLP-1 Glory or Diversified Dividend? Novo Nordisk vs. Amgen in Weight Loss Race

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.
AMGNLLYNVOclinical trialsmarket share
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Cytokines Market Set to Nearly Double to $174.5B by 2032

Global cytokines market projected to grow from $95.32B (2025) to $174.53B (2032) at 9.02% CAGR, driven by manufacturing advances and strategic partnerships.
AMGNBMYCELGrJNJMRK+6strategic partnershipssupply chain resilience
BenzingaBenzinga··Prnewswire

Amgen Raises Q2 2026 Dividend to $2.52 Per Share, Signals Confidence

Amgen declared $2.52 per share dividend for Q2 2026, payable June 5, while advancing pipeline in cancer, cardiovascular, and obesity treatments.
AMGNshareholder returnsdividend announcement
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Market Set to Nearly Triple to $137B by 2030 as Drug Class Expands Beyond Diabetes

GLP-1 receptor agonist market projected to surge from $51.9B in 2024 to $137.4B by 2030, driven by obesity prevalence and expanded therapeutic applications.
AMGNPFELLYNVORHHBY+1weight lossdiabetes treatment
The Motley FoolThe Motley Fool··Motley Fool Staff

26 Years Later: How One Couple's Money Manifesto Held Up Through Market Cycles

Robert Brokamp and wife Elizabeth revisit their 26-year-old financial manifesto, evaluating five core principles for couples managing money together and sharing lessons learned.
AMGNAXPMSFTCATHD+1financial planningfinancial manifesto
GlobeNewswire Inc.GlobeNewswire Inc.··Fight Colorectal Cancer (Fight Crc)

Colorectal Cancer Deaths Surge Among Young Americans as Awareness Campaign Returns

Colorectal cancer deaths surge among Americans under 50, becoming the leading cancer killer in this age group. An awareness campaign installs 27,000 blue flags on the National Mall.
AMGNBMYCELGrJNJMRK+1colorectal cancercancer awareness
GlobeNewswire Inc.GlobeNewswire Inc.··Spherix Global Insights

Rheumatologists Split on Sotyktu's Market Impact Ahead of FDA Decision

BMS's Sotyktu shows promise for psoriatic arthritis among one-third of surveyed rheumatologists, but analysts expect modest market capture ahead of March 2026 FDA decision.
AMGNBMYCELGrJNJPFE+1psoriatic arthritisTYK2 inhibitor
GlobeNewswire Inc.GlobeNewswire Inc.··American Kidney Fund

American Kidney Fund Launches National Awareness Campaign Amid Rising Disease Prevalence

American Kidney Fund launches "Kidneys Count" campaign March 1, 2026, promoting early detection and prevention of kidney disease affecting 1 in 7 American adults.
AMGNARGXNVSTVTXkidney diseaseearly detection
BenzingaBenzinga··Bamboo Works

VivaVision Races to Complete Hong Kong IPO as Cash Runway Narrows

VivaVision Biotech rushes Hong Kong IPO as cash reserves dwindle to $5.2 million against $6.3 million quarterly burn rate. Two late-stage eye disease candidates drive investor appeal.
AMGNABTcash burnclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Bcc Research

Advanced Drug Delivery Systems Market Set to Reach $487B by 2030

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.
AMGNBMYCELGrJNJPFE+3personalized medicineAsia-Pacific